Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

141 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Analysis and visualization of the course and burden over time of adverse drug reactions (ADRs) attributed to TNFα-inhibitors in patients with inflammatory rheumatic diseases (IRDs).
de Boer M, Gosselt HR, Jansen J, van Doorn MBA, Hoentjen F, Nurmohamed MT, Spuls PI, Tas SW, Vonkeman HE, Jessurun NT. de Boer M, et al. Among authors: vonkeman he. Expert Opin Drug Saf. 2023 Mar;22(3):195-202. doi: 10.1080/14740338.2022.2110237. Epub 2022 Aug 10. Expert Opin Drug Saf. 2023. PMID: 35946722
Rheumatoid arthritis-specific cardiovascular risk scores are not superior to general risk scores: a validation analysis of patients from seven countries.
Crowson CS, Gabriel SE, Semb AG, van Riel PLCM, Karpouzas G, Dessein PH, Hitchon C, Pascual-Ramos V, Kitas GD; Trans-Atlantic Cardiovascular Consortium for Rheumatoid Arthritis. Crowson CS, et al. Rheumatology (Oxford). 2017 Jul 1;56(7):1102-1110. doi: 10.1093/rheumatology/kex038. Rheumatology (Oxford). 2017. PMID: 28339992 Free PMC article.
Stakeholders' perspectives on a patient-reported outcome measure-based drug safety monitoring system for immune-mediated inflammatory diseases.
Kosse LJ, Jessurun NT, Vonkeman HE, Tas SW, Nurmohamed MT, Hoentjen F, van Doorn MBA, van Puijenbroek EP, van den Bemt BJF, de Vries M. Kosse LJ, et al. Among authors: vonkeman he. Expert Opin Drug Saf. 2020 Nov;19(11):1521-1528. doi: 10.1080/14740338.2020.1803826. Epub 2020 Aug 12. Expert Opin Drug Saf. 2020. PMID: 32730115
Gastrointestinal Adverse Drug Reaction Profile of Etanercept: Real-world Data From Patients and Healthcare Professionals.
van Lint JA, Jessurun NT, Tas SW, van den Bemt BJF, Nurmohamed MT, van Doorn MBA, Spuls PI, van Tubergen AM, Ten Klooster PM, van Puijenbroek EP, Hoentjen F, Vonkeman HE. van Lint JA, et al. Among authors: vonkeman he. J Rheumatol. 2021 Sep;48(9):1388-1394. doi: 10.3899/jrheum.201373. Epub 2021 May 15. J Rheumatol. 2021. PMID: 33993115
Patients' perspectives on a drug safety monitoring system for immune-mediated inflammatory diseases based on patient-reported outcomes.
Kosse LJ, Weits G, Vonkeman HE, Tas SW, Hoentjen F, Van Doorn MB, Spuls PI, D'Haens GR, Nurmohamed MT, van Puijenbroek EP, Van Den Bemt BJ, Jessurun NT. Kosse LJ, et al. Among authors: vonkeman he. Expert Opin Drug Saf. 2021 Dec;20(12):1565-1572. doi: 10.1080/14740338.2021.1963436. Epub 2021 Aug 12. Expert Opin Drug Saf. 2021. PMID: 34348543
Hypoglycaemia following JAK inhibitor treatment in patients with diabetes.
van Lint JA, van Hunsel FPAM, Tas SW, Vonkeman HE, Hoentjen F, van Doorn MBA, Hebing RCF, Nurmohamed MT, van den Bemt BJF, van Puijenbroek EP, Jessurun NT. van Lint JA, et al. Among authors: vonkeman he. Ann Rheum Dis. 2022 Apr;81(4):597-599. doi: 10.1136/annrheumdis-2021-221840. Epub 2021 Dec 16. Ann Rheum Dis. 2022. PMID: 34916208 No abstract available.
141 results